As of 2026-06-13, the Intrinsic Value of Shanghai Haishun New Pharmaceutical Packaging Co Ltd (300501.SZ) is 0.89 CNY. This 300501.SZ valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 13.09 CNY, the upside of Shanghai Haishun New Pharmaceutical Packaging Co Ltd is -93.20%.
The range of the Intrinsic Value is (0.07) - 3.48 CNY
Based on its market price of 13.09 CNY and our intrinsic valuation, Shanghai Haishun New Pharmaceutical Packaging Co Ltd (300501.SZ) is overvalued by 93.20%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | (0.07) - 3.48 | 0.89 | -93.2% |
| DCF (Growth 10y) | 3.70 - 14.53 | 6.63 | -49.4% |
| DCF (EBITDA 5y) | 17.43 - 49.56 | 34.30 | 162.0% |
| DCF (EBITDA 10y) | 19.86 - 64.55 | 41.13 | 214.2% |
| Fair Value | -0.92 - -0.92 | -0.92 | -107.05% |
| P/E | (4.07) - 2.33 | (2.57) | -119.6% |
| EV/EBITDA | (3.08) - 12.47 | 3.83 | -70.7% |
| EPV | (5.50) - (7.29) | (6.40) | -148.9% |
| DDM - Stable | (1.09) - (3.60) | (2.34) | -117.9% |
| DDM - Multi | 3.57 - 9.86 | 5.33 | -59.3% |
| Market Cap (mil) | 3,641.38 |
| Beta | 1.08 |
| Outstanding shares (mil) | 278.18 |
| Enterprise Value (mil) | 4,159.38 |
| Market risk premium | 6.13% |
| Cost of Equity | 12.25% |
| Cost of Debt | 5.00% |
| WACC | 10.78% |